Tag: clinical study
Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...
Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Study: Intranasal Epinephrine Absorbed Faster Than Injection and Even Better with...
Study compared absorption of epinephrine via nasal spray to that of intramuscular injection.
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT
Continuing with a modest dose confers more protection, NIH-funded study finds.
New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...
UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Recruitment of Infants Begins for Phase 3 Trial of Cream to...
The trial needs 760 babies aged three weeks or younger whose parents or siblings suffer from either eczema, asthma or food allergies.
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...
NIH and partners to assess whether Omalizumab can reduce allergic reactions.
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food...
First clinical study of a bacterial consortium for treating food allergy will initially be studied in patients with history of peanut allergy.
